Twist Bioscience Co. (NASDAQ:TWST) Director Sells $170,136.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,600 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares of the company’s stock, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Twist Bioscience Price Performance

Shares of TWST opened at $36.89 on Friday. Twist Bioscience Co. has a one year low of $18.80 and a one year high of $60.90. The business has a fifty day moving average of $43.90 and a 200 day moving average of $45.91. The firm has a market capitalization of $2.16 billion, a P/E ratio of -9.66 and a beta of 1.78.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SageView Advisory Group LLC bought a new stake in Twist Bioscience during the first quarter valued at approximately $1,144,000. Susquehanna Fundamental Investments LLC bought a new position in Twist Bioscience in the 1st quarter worth $300,000. Sei Investments Co. lifted its position in Twist Bioscience by 32.7% during the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after purchasing an additional 55,124 shares in the last quarter. Silvercrest Asset Management Group LLC grew its holdings in Twist Bioscience by 38.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock valued at $4,605,000 after purchasing an additional 37,376 shares during the period. Finally, Principal Financial Group Inc. increased its position in Twist Bioscience by 210.2% in the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of analyst reports. Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays dropped their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.